Meta wins AI copyright case filed by Sarah Silverman and other authors
Federal Judge Vince Chhabria has ruled in favor of Meta over the 13 book authors, including Sarah Silverman, who sued the company for training its large language model on their published work without obtaining consent. His court has granted summary judgment to Meta, which means the case didn't reach full trial. Chhabria said that Meta didn't violate copyright law after the plaintiffs had failed to show sufficient evidence that the company's use of the authors' work would hurt them financially.
In his ruling (PDF), Chhabria admitted that in most cases, it is illegal to feed copyright-protected materials into their large language models without getting permission or paying the copyright owners for the right to use their creations. "...by training generative AI models with copyrighted works, companies are creating something that often will dramatically undermine the market for those works, and thus dramatically undermine the incentive for human beings to create things the old-fashioned way," he wrote.
However, the court "must decide cases based on the evidence presented by the parties," he said. For this particular case, the plaintiffs argued that Meta's actions cannot be considered "fair use." They said that that their creations are affected by Meta's use because the company's LLM, Llama, is capable of reproducing small snippets of text from their books. They also said that by using their books for training without consent, Meta had diminished their ability to license their work for LLM training. The judge called both arguments "clear losers." Llama isn't capable of generating enough text straight from the books to matter, he said, and the authors aren't entitled to the "market for licensing their works as AI training data."
Chhabria wrote that the argument that Meta copied their books to create a product that has the capability to flood the market with similar works, thereby causing market dilution, could have given the plaintiffs the win. But the plaintiffs barely touched the argument and presented no evidence to show how output from Meta's LLM could dilute the market. Despite his ruling, Chhabria clarified that his decision is limited: It only affects the 13 authors in the lawsuit and "does not stand for the proposition that Meta's use of copyrighted materials to train its language models is lawful."
Another judge, William Alsup, also recently sided with Anthropic in a class action lawsuit also brought by a group of authors who accused the company of using their copyrighted work without permission. Alsup provided the writers recourse, though, and allowed them to take Anthropic to court for piracy.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
The healthcare sector offers an abundance of high-growth investment opportunities. Companies leveraging artificial intelligence and genomic medicine are delivering innovative therapies with significant potential. Small-cap and under-the-radar stocks with strong growth possibilities merit closer investor attention. 10 stocks we like better than TransMedics Group › There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving. Investors stand to benefit as healthcare leaders and emerging players address the needs of an aging global population and the rising prevalence of chronic diseases. Here are 10 under-the-radar healthcare stocks that could be great buys for your portfolio. Certara (NASDAQ: CERT) is poised to capitalize on the transformation in medicine driven by artificial intelligence (AI), providing bio-simulation software and services that accelerate drug development. The company plays a crucial role in the pharmaceutical industry. Over 90% of all novel drugs approved by the Food and Drug Administration (FDA) since 2014 have leveraged its technology. Its AI-driven solutions enhance research and development (R&D), enabling faster and more precise drug development. Certara deserves a closer look by investors seeking to tap into the AI-driven healthcare transformation. Beam Therapeutics (NASDAQ: BEAM) is a clinical-stage biotech pioneering precision-based gene editing therapies for genetic diseases, including sickle cell disease. Its innovative technology enables precise single-nucleotide DNA changes, potentially offering a safer alternative to traditional CRISPR genetic engineering. Beam has reported early success in gene correction, with its lead candidate, BEAM-101, in phase 1/2 trials for sickle cell disease. While the company still has a lot to prove, its differentiated approach and clinical progress position it for remarkable growth in the long term. Inspire Medical Systems (NYSE: INSP) develops implantable neurostimulation devices for obstructive sleep apnea, offering its FDA-approved Inspire therapy as a noninvasive alternative to CPAP machines. In its first quarter (the period ended March 31), revenue surged 23% year over year to $201 million, driven by growing U.S. adoption and new international approvals. With increasing demand for sleep apnea treatment, Inspire has a significant opportunity to capture market share. Insulet (NASDAQ: PODD) specializes in tubeless insulin pump technology. Its Omnipod system simplifies diabetes management for Type 1 and insulin-dependent Type 2 patients globally, offering convenience and improved outcomes. With a 2025 revenue growth target of 19% to 22%, the company is poised for continued expansion, particularly in underpenetrated international markets. Insulet's strong growth trajectory positions it to reward shareholders further. Krystal Biotech (NASDAQ: KRYS) focuses on rare skin diseases. Its FDA-approved gene therapy, Vyjuvek, for dystrophic epidermolysis bullosa (fragile skin that blisters easily) is expected to approach $400 million in revenue this year, solidifying its position as a best-in-class treatment. Vyjuvek's success validates Krystal's R&D, bolstering confidence in its pipeline and unlocking added market potential. LifeMD (NASDAQ: LFMD) operates a telehealth platform providing specialized virtual care in weight loss, men's health, and dermatology. A partnership with Novo Nordisk to offer Wegovy, a leading GLP-1 treatment, has driven impressive growth, with first-quarter revenue surging 49% year over year for the period ended March 31. LifeMD could expand its growing user base into a comprehensive health management ecosystem to fuel growth and solidify its telehealth leadership. Option Care Health (NASDAQ: OPCH) is the leading U.S. provider of home and alternative-site infusion services, delivering crucial therapies for chronic and acute conditions like cancer, immune deficiencies, and infections. As the healthcare industry shifts toward more personalized and cost-effective care, Option Care Health is in position to capitalize on the strong demand, with its extensive network and high-quality services. Tempus AI (NASDAQ: TEM) harnesses artificial intelligence to advance precision medicine, using its collection of clinical and molecular data from more than 40 million patients to power diagnostics in oncology, cardiology, and beyond. The company projects its revenue to climb by more than 80% this year, to about $1.3 billion. Tempus AI's scalable platform and extensive data ecosystem present substantial opportunities for expansion and impact in personalized healthcare. TransMedics Group (NASDAQ: TMDX) has revolutionized organ transplantation with its Organ Care System (OCS), the only FDA-approved device for heart, lung, and liver transplants that extends organ preservation time. The company's projected revenue growth of 30% this year underscores the strong momentum in a global expansion opportunity. Veeva Systems (NYSE: VEEV) offers cloud-based software that streamlines clinical, regulatory, and commercial processes for life sciences companies. Serving over 1,000 customers, including major pharmaceutical companies and emerging biotechs, Veeva's platform is well positioned to capitalize on the industry's increasing reliance on digital solutions for innovation and compliance. Before you buy stock in TransMedics Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and TransMedics Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Dan Victor has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Beam Therapeutics, Inspire Medical Systems, TransMedics Group, and Veeva Systems. The Motley Fool recommends Insulet, Krystal Biotech, and Novo Nordisk. The Motley Fool has a disclosure policy. 10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential was originally published by The Motley Fool
Yahoo
39 minutes ago
- Yahoo
Corus Entertainment Third Quarter 2025 Earnings: CA$0.04 loss per share (vs CA$3.86 loss in 3Q 2024)
Revenue: CA$297.8m (down 10% from 3Q 2024). Net loss: CA$7.34m (loss narrowed by 99% from 3Q 2024). CA$0.04 loss per share (improved from CA$3.86 loss in 3Q 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Looking ahead, revenue is expected to decline by 7.2% p.a. on average during the next 3 years, while revenues in the Media industry in North America are expected to grow by 2.8%. Performance of the market in Canada. The company's share price is broadly unchanged from a week ago. We don't want to rain on the parade too much, but we did also find 3 warning signs for Corus Entertainment (2 are significant!) that you need to be mindful of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
41 minutes ago
- Yahoo
If I Could Only Buy 1 Artificial Intelligence (AI) Stock, It Would Be This Monster "Magnificent Seven" Member Approved by Billionaires Warren Buffett and Bill Ackman
Earlier this year, Bill Ackman bought a megacap AI stock -- joining Warren Buffett as a high-profile shareholder. Ackman and Buffett are both value investors, making the timing of Ackman's purchase particularly brilliant. While the markets have been moving higher over the last several weeks, Amazon remains my top pick. 10 stocks we like better than Amazon › Bill Ackman is a billionaire investor and serves as CEO to the hedge fund Pershing Square Capital Management. Throughout the artificial intelligence (AI) revolution, Pershing Square's primary exposure to the stock market's latest megatrend has been through a position in Alphabet. Recently, however, Ackman made headlines after it was revealed that Pershing Square complemented its Alphabet position with another member of the "Magnificent Seven": Amazon (NASDAQ: AMZN). Interestingly, Amazon is one of the few technology stocks featured in Warren Buffett's portfolio at Berkshire Hathaway. Let's explore why billionaire investors like Buffett and Ackman may have taken a liking to Amazon. Moreover, I'll break down why the e-commerce and cloud computing giant is my top pick among AI stocks. Ackman and Buffett built their fortunes in different ways. Buffett is best known for building positions in globally recognized brands and holding onto these stocks over the course of many years or even decades. In addition, many of Buffett's most lucrative investments have come from companies that consistently buy back stock or pay a dividend. Lastly, Buffett generally sticks to industries such as financial services, energy, and consumer goods -- rarely exposing Berkshire to more volatile markets such as the technology sector. On the other hand, Ackman tends to be a bit more industry-agnostic compared to Buffett. Moreover, from time to time Ackman will also profit from more sophisticated trading techniques that involve derivatives. One philosophy that Buffett and Ackman do share, however, is their love for value stocks. Neither investor is known for chasing momentum or overpaying for a stock trading with a lofty valuation. The chart above benchmarks Amazon's price action relative to other megacap AI and cloud computing stocks. While each stock above faced some pressure earlier this year, Amazon's decline was more pronounced relative to its peers -- specifically throughout April. This is when Ackman pounced, buying the dip in Amazon stock during a period of notable valuation contraction. Furthermore, I think Amazon's diversified ecosystem spanning online shopping, cloud computing, subscription services, logistics, robotics, grocery delivery, streaming and entertainment, and more is another factor that played a role in the tech giant earning a spot in both Berkshire's and Pershing Square's portfolios. By operating across so many different end markets, Amazon is able to thrive under various economic conditions while also appealing to several different customer demographics. Buffett and Ackman may favor business models like this as it helps mitigate risk factors such as cyclicality, seasonality, and growth unpredictability. Given the ideas explored above, Amazon may not appear to be a traditional AI opportunity. But over the last few years, Amazon has quietly been transforming its business through a series of AI-driven investments. For starters, the company invested $8 billion into a start-up called Anthropic. Anthropic has become a key integration in Amazon Web Services (AWS), leading to sustained acceleration across revenue and profitability in the company's cloud computing business. Amazon is also deploying AI robotics throughout its fulfillment centers. This move has the potential to generate significant cost savings by bringing new levels of automation and efficiency to the company's warehouses. Moreover, while companies like IonQ or Rigetti Computing fetch the majority of attention in the quantum computing arena, Amazon is developing its own line of chipsets: Trainium, Inferentia, and Ocelot. Based on forward earnings multiples, Amazon stock isn't exactly a bargain right now. My hunch is that Amazon's diverse business and robust growth prospects may make the company appear to be more of a safe haven relative to other volatile, unpredictable opportunities in the AI realm. Even so, I don't think Amazon has experienced the same level of valuation expansion that some of its Magnificent Seven peers (e.g., Microsoft, Nvidia) have over the last couple of years. Furthermore, given how many different businesses AI stands to disrupt within the Amazon ecosystem, I think the company is uniquely positioned for sustained periods of robust growth. With that in mind, I think Amazon still has significant upside and I see a position in the stock as a superior opportunity compared to its peers. Investors with a long-run time horizon may want to consider initiating a position in Amazon stock despite its slight premium right now. Before you buy stock in Amazon, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Amazon wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Adam Spatacco has positions in Alphabet, Amazon, Microsoft, and Nvidia. The Motley Fool has positions in and recommends Alphabet, Amazon, Berkshire Hathaway, Microsoft, Nvidia, and Oracle. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. If I Could Only Buy 1 Artificial Intelligence (AI) Stock, It Would Be This Monster "Magnificent Seven" Member Approved by Billionaires Warren Buffett and Bill Ackman was originally published by The Motley Fool